Guardant Health Inc (GH)vsEli Lilly and Company (LLY)
GH
Guardant Health Inc
$125.61
-5.60%
HEALTHCARE · Cap: $17.45B
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 6588% more annual revenue ($72.25B vs $1.08B). LLY leads profitability with a 35.0% profit margin vs -40.1%. LLY earns a higher WallStSmart Score of 78/100 (B+).
GH
Avoid31
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 48.3% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
ROE of -4584.0% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : GH
The strongest argument for GH centers on Revenue Growth, Debt/Equity. Revenue growth of 48.3% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : GH
The primary concerns for GH are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
GH profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
GH carries more volatility with a beta of 1.62 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 31/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Guardant Health Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?